F&G Annuities & Life heads into its Q1 2026 earnings call — scheduled for May 7 — with CEO Christopher Blunt having put real money behind the stock at prices well below where it trades today.
The most striking data point this week is what happened inside the company two months ago. On March 13, Blunt bought 10,000 shares at $20.99, spending just over $209,000 of his own money. An independent director, Celina Doka, added another 4,760 shares the same day at a nearly identical price. The stock has since climbed more than 40% to $29.42, closing up nearly 4% on Tuesday and up 2.8% on the week. The 90-day net insider position is a positive $1.6 million, skewed by those March purchases — a meaningful signal heading into a catalyst. The CFO did sell 10,566 shares on April 1 at $25.79, but that looks like routine profit-taking after the run-up rather than a shift in conviction.
The borrow market paints a low-pressure picture. Short interest runs at 2.05% of the free float — modest for a life insurer — but the direction of travel is worth noting. Short interest has risen roughly 75% over the past month, from around 1.57 million shares in late March to 2.76 million today. That build happened in a straight line through April. Availability remains ample, consistent with a borrowing market that is loose rather than stressed: cost to borrow is just 0.57%, barely moved over the month. The short score of 50 sits at the mid-point of the universe — neither extreme. This is a stock where shorts are gradually adding but are far from crowded.
Options positioning is notably calm ahead of results. The put/call ratio runs at 0.72, fractionally below its 20-day average of 0.73, with a z-score near zero. There is no sign of late hedging or defensive accumulation in the options market. The RSI14 is elevated at 71, consistent with the sharp one-month price recovery of 12.9%, but the PCR data does not suggest that options traders are bracing for a reversal.
The Street is cautious on valuation. The only visible recent analyst action comes from Barclays, which cut its target from $31 to $27 on April 8 — roughly a month ago — while keeping an Equal-Weight rating. With FG now trading at $29.42, the stock has moved through that target. The analyst consensus return potential sits at -8.2%, meaning the average target is below the current price. The P/E of 7.1x and P/B near 1.0x do not suggest the market is paying a premium, but the Street's target suggests it may have run ahead of where analysts currently see fair value. EPS surprise ranks only in the 39th percentile — the company has not been a consistent beat machine. That makes the upcoming print more important than usual.
The earnings history is sobering context. The last quarterly result, reported in February, knocked the stock down 15.8% on the day and 18.2% over the five sessions that followed. That was a severe reaction. Blunt's decision to buy heavily in mid-March — roughly three weeks after that decline — adds weight to the insider signal, but it also illustrates how violently this name can move around results. Close peer PRU gained 3.5% on the week and MET added 2.1%, suggesting the broader insurance group has been recovering in tandem. Parent company FNF was the outlier, slipping 2.8% on the week.
What to watch on May 7: whether the quarterly release produces a divergence between the CEO's evident conviction and the Street's revised-down targets — and how the short interest trend that built steadily through April responds to the print.
See the live data behind this article on ORTEX.
Open FG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
